Lipid-lowering And Anti-inflammatory Effects Of Tetradecylthioacetic Acid In HIV-infected Patients On Highly Active Antiretroviral Therapy

Effect None
Trial Design Cohort
Trial Length 2-4 Weeks
Number of Subjects 10
Sex Both Genders
Age Range 30-44, 45-64
Body Types Average
Notes for this study:
In persons with HIV who were already on anti-viral therapy, controlling the diet and then supplementing TTA (1,000mg in four divided doses for four weeks) exerted hypolipidemic and anti-inflammatory properties yet did not influence viral loads in the tested immune cells. No placebo group was used.

The decrease in apolipoprotein B was trending to, but did not reach, statistical significance (P = 0.08). The decrease in triglycerides seen was not additive with the dietary treatment and was not seen as evidence for the efficacy of TTA.